FDA NDAC MEMBERS TONG, SLINGLUFF CONFIRMED, EFFECTIVE SEPT. 4,
This article was originally published in The Tan Sheet
FDA NDAC MEMBERS TONG, SLINGLUFF CONFIRMED, EFFECTIVE SEPT. 4, in time for the two new appointees to sit on the analgesic indications subcommittee, which is comprised of all Nonprescription Drugs Advisory Committee members and two members from the Arthritis Advisory Committee. The subcommittee is scheduled to meet Sept. 8-9. The two new members are Theodore Tong, PharmD, University of Arizona and Beth Slingluff, Carondelet St. Mary's Hospital, Tucson, Ariz. ("The Tan Sheet" Aug. 1, In Brief).
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC